IP Library Granted Patent US 11,268,157
Granted Patent B2
US 11,268,157 · App. 16/891,018 · Granted Mar 8, 2022

Method for producing RNA

Inventors: Florian Von Der Mülbe (Stuttgart, DE); Ladislaus Reidel (Rottenburg am Neckar, DE); Thomas Ketterer (Gomaringen, DE); Lilia Gontcharova (Reutlingen, DE); Susanne Bauer (Bodelshausen, DE); Steve Pascolo (Zurich, CH); Jochen Probst (Wolfschlugen, DE); Andreas Schmid (Sigmaringen, DE)
Assignee: CureVac Real Estate GmbH
C12Q1/689C12N15/1003C12P19/34C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,268,157
App. No.
16/891,018
Granted
Mar 8, 2022
Kind
B2
Abstract

The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.

Claims (36)

1. A method for producing purified mRNA on a preparative scale comprising the following steps:

a) providing a template DNA comprising a nucleic acid sequence encoding an mRNA;

b) in vitro transcribing the template DNA in order to obtain a composition comprising the mRNA; and

c) purifying a preparative quantity of the mRNA obtained in step b) by purification steps comprising, at least:

i) oligo dT-based affinity purification; and

ii) core bead chromatography,

thereby producing a preparative quantity of purified mRNA.

2. The method of claim 1 , wherein the oligo dT-based affinity purification is performed before the core bead chromatography.

3. The method of claim 1 , wherein the core bead chromatography is performed before the oligo dT-based affinity purification.

4. The method of claim 1 , wherein the core bead chromatography is performed using a core bead flow-through chromatography medium.

5. The method of claim 1 , wherein the core bead chromatography is performed on a liquid chromatography system.

6. The method of claim 1 , wherein the core bead chromatography is a core bead flow-through chromatography.

7. The method of claim 1 , wherein the core bead chromatography is performed in a way that the template DNA and proteins are captured in the beads, and RNA products flow through.

8. The method of claim 1 , wherein the following steps are used to control the quality of the template DNA provided in step a):

I) determining the concentration of the template DNA in a sample;

II) determining the integrity of the template DNA;

III) determining the identity of the template DNA; and/or

IV) determining the purity of the template DNA.

9. The method of claim 1 , wherein the following steps are used to assess the quality of the mRNA obtained in steps b) or c):

i) determining the concentration of the mRNA or the purified mRNA in a sample;

ii) determining the integrity of the mRNA or the purified mRNA;

iii) determining the identity of the mRNA or the purified mRNA;

iv) determining the purity of the mRNA or the purified mRNA;

v) determining the pH of a sample comprising the mRNA or the purified mRNA;

vi) determining the osmolality of a sample comprising the mRNA or the purified mRNA;

vii) determining the presence and/or the amount of the template DNA in a sample comprising the mRNA or the purified mRNA; and/or

viii) determining the presence and/or the amount of an organic solvent in a sample comprising the mRNA or the purified mRNA.

10. The method of claim 1 , wherein the purified mRNA obtain in step c) comprises 1 to 5 grams of mRNA.

11. The method of claim 1 , wherein step a) comprises synthesis of the template DNA.

12. The method of claim 1 , wherein the template DNA is a DNA plasmid.

13. The method of claim 1 , wherein the in vitro transcription in step b) is carried out in presence of modified nucleotides.

14. The method of claim 1 , wherein the purification in step c) further comprises a step of RP-HPLC.

15. The method of claim 1 , wherein the purification in step c) further comprises a precipitation step.

16. The method of claim 15 , wherein the precipitation step is an alcoholic precipitation step or a LiCl precipitation step.

17. The method of claim 1 , wherein the purification in step c) comprises a further chromatographic step selected from the group consisting of anion exchange chromatography, affinity chromatography, and hydroxyapatite chromatography.

18. The method according to claim 1 , wherein the mRNA obtained in step b) or the purified mRNA obtained in step c) is lyophilized.

Assignments (1)
CHANGE OF NAME Recorded Nov 12, 2022
From: CUREVAC REAL ESTATE GMBH
To: CUREVAC MANUFACTURING GMBH
Reel/Frame 061932/0502 →
Continuity (4)
Continuation 16005131 · Jun 11, 2018
Continuation 15044094 · Feb 15, 2016
Continuation PCTEP2015000959 · May 8, 2015
Related Publication 20200308634A1 · Oct 1, 2020
Cited By (16)
US 12,201,680 US 12,221,605 US 12,227,549 US 12,240,873 US 12,318,444 US 12,337,031 US 12,385,088 US 12,442,005 US 12,460,204 US 12,492,420 US 12,514,918 US 12,527,856 US 12,528,855 US 12,533,422 US 12,618,060 US 12,649,914